Heena Shah Patel
Allergy & Immunology · Upland, CANPI 1881916864
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $292,090 of the $427,983 with a category attached, or 68.2%. GSK accounts for 91.6% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $140,239 and has fallen 50.1% since, to $70,030 in 2025. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,233 payments — averaging $347.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$392K
- Incyte Corporation$8K
- Sanofi$8K
- Regeneron$5K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $9K from 33 others
Across 113 payments — averaging $2353.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$62K
- Sanofi$60K
- GSK$50K
- Genentech, Inc.$43K
- Astrazeneca UK Limited$34K
- Mylan Specialty L.p.$8K
- plus $8K from 2 others
What the payments were for
- Consulting fees$31,2887%
- Speaking & faculty fees$292,09068%
- Travel & lodging$76,52718%
- Food & beverage$27,3266%
- Education$7360%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 499 | $391,960 |
| Incyte Corporation | 23 | $8,305 |
| Sanofi | 90 | $7,519 |
| Regeneron | 11 | $5,493 |
| AstraZeneca | 103 | $3,441 |
| Regeneron Healthcare Solutions, Inc. | 87 | $1,900 |
| CSL Behring | 59 | $1,195 |
| Pfizer | 64 | $1,184 |
| LEO Pharma Inc. | 47 | $940 |
| AbbVie | 39 | $917 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $783 |
| Pharming Healthcare, Inc. | 12 | $444 |
| Sanofi-aventis U.S. LLC | 5 | $426 |
| Optinose US, Inc. | 32 | $381 |
| Biocryst US Sales Co., LLC | 15 | $364 |
| Amgen(2 entities) | 12 | $322 |
| Genentech USA, Inc. | 15 | $312 |
| Novartis | 11 | $249 |
| Boehringer Ingelheim | 6 | $213 |
| Teva Pharmaceuticals USA, Inc. | 11 | $196 |
| Octapharma USA, Inc. | 4 | $182 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $148 |
| Sunovion Pharmaceuticals Inc. | 8 | $142 |
| Merck | 3 | $142 |
| Genentech, Inc. | 2 | $129 |
| Blueprint Medicines Corporation | 5 | $115 |
| Kaleo, Inc. | 6 | $107 |
| Alk-abello, Inc | 4 | $87 |
| Galderma Laboratories, L.p. | 3 | $76 |
| Grifols USA, LLC | 3 | $61 |
| Shire North American Group Inc | 3 | $55 |
| Phadia US Inc. | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $33 |
| Mylan Specialty L.p. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$427,983 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $249,802 |
| Dupixent SyringeDupilumab | 37 | $138,229 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $89,828 |
| Dupixent PenDupilumab | 16 | $67,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $21,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $16,322 |
| Cromolyn Sodium | 15 | $4,484 |
| Epinephrine | 12 | $2,616 |
| Tacrolimus | 11 | $2,180 |
| Azelastine Hcl | 39 | $1,323 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,214 |
| Ipratropium Bromide | 22 | $449 |
| Fluticasone Propionate | 25 | $382 |
| Montelukast Sodium | 37 | $298 |
| Triamcinolone Acetonide | 21 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga | $1,184 | $249,80226 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $783 | $89,82811 claims |
| GSKTrelegy Ellipta | $391,960 | $21,82729 claims |
| AstraZenecaBreztri Aerosphere | $3,441 | $16,32216 claims |
| Hikma Pharmaceuticals USAEpinephrine | $33 | $2,61612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Upland
- Amit PatelUpland$86K
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.